Agent nonsedating antihistamine
Although severe hypersensitivity reactions are rare, the incidence of mild-to-moderate reactions may be underestimated in the oncology community , resulting in a lack of preparedness or unfamiliarity with the grading and management of hypersensitivity reactions.
Severe reactions may require treatment discontinuation. The different time of onset should be considered when developing strategies for preventing and managing hypersensitivity reactions.
However, 10%–30% of reactions to monoclonal antibodies are delayed, and may occur in later infusions, indicating the importance of close observation of the patient following administration.
Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and symptom management.
Emphasis was placed on articles that provided practical information on hypersensitivity reaction management.
Data found in the literature were supplemented with information from the package insert for each agent. Severe hypersensitivity reactions are rare, with an incidence of ≤5%, provided patients receive proper premedication, close monitoring, and prompt intervention when symptoms occur.
Nearly all systemic agents used in cancer treatment today are associated with possible hypersensitivity reactions .